Erythropoietin stimulating agents in the management of anemia of chronic kidney disease

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 195-200

  Hayat, Amir ^a   Haria, Dhiren ^a   Salifu, Moro O ^a  

^a Downstate Health Sciences University   (United States)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin stimulating agents

Indexed keywords

EID: 84866651212     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S2356     Document Type: Review

References (34)

1. Barany H-J, Muller. 2007. Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant, 22(Suppl 4):iv10-iv18.
2. Brugnara C. 2003. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem, 49:1573-8.
3. Collins A. J, Ma JZ, Ebben J. 2000. Impact of hematocrit on morbidity and mortality. Semin Nephrol, 20:345.
4. Coyne, DW, Kapoian, T, Suki, W, et al. 2007. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol, 18:975.
5. Drueke T. B, Locatelli F, Clyne N, et al. 2006. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med, 355:2071-84.
6. Eschbach J. W, Kelly MR, Haley NR, et al. 1989. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med, 20:158-63.
7. Fishbane S., Frei GL, Maesaka J. 1995. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis, 26:41-6.
8. Foley R.N. 2006. Do we know the correct hemoglobin target for anemic patients with chronic kidney disease? Clin J Am Soc Nephrol, 1:678-84.
9. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa) [online] Accessed July 17, 2008. URL: http://www.fda. gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm.
10. Jurkovitz C. T, Abramson JL, Vaccarino LV, et al. 2003. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol, 14:2919.
11. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease. 2007. Update of hemoglobin target Am J Kidney Dis, 50:471-530.
12. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. 2006. Am J Kidney Dis, 47:S11-145.
13. Le Meur Y, Lorgeot V, Comte L, et al. 2001. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis, 38:510-7.
14. Levey A. S, Coresh J, Balk E, et al. 2003. National Kidney Foundation Disease Outcomes Quality Initiative Clinic Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Ann Intern Med, 139:137-47.
15. Ma J. Z, Ebben J, Xia, H Collins, AJ. 1999. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol, 10:610.
16. Macdougall I.C. 2008. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol, 3:200-7.
17. Mae Thamer, Yi Zhang, James Kaufman, et al. 2007. Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis. JAMA, 297:1667-74.
18. Maxwell P. H, Osmond MK, Pugh CW, et al. 1993. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int, 44:1149.
19. McClellan W, Aronoff SL, Bolton WK, et al. 2004. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin, 20:1501-10.
20. McClellan WM, Flanders WD, Langston RD, et al. 2002. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol, 13:1928.
21. McFarlane SI, Salifu MO, Makaryus J, et al. 2006. Anemia and cardiovascular disease in diabetic nephropathy. Curr Diab Rep, 6:213-8.
22. Mohanram A., Zhang Z, Shahinfar S, et al. 2008. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int, 73:630-6.
23. Ortega O., Rodriguez I, Gallar P, et al. 2002. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant, 17:1105-9.
24. Pollock C., Johnson DW, Hörl WH, et al. 2008. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol, 3:193-9. Public Health Advisory: Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp) [online] Accessed July 17, 2008. URL:http://www.fda.gov/cder/drug/advisory/RHE.htm.
25. Ratcliffe, PJ, Ebert, BL, Ferguson, DJ, et al. 1995. Regulation of the erythropoietin gene. Nephrol Dial Transplant, 10(Suppl 2):18.
26. Righetti M., Ferrario GM, Milani S, et al. 2004. A single centre study about the effects of HFR on anemia. G Ital Nefrol, 21(Suppl 30):S168-71.
27. Singh A. K, Szczech L, Tang KL, et al. 2006. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med, 355:2085-98.
28. Tonelli M., Blake PG, Muirhead N. 2001. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J, 47:82-5.
29. Tonelli M., Winkelmayer WC, Jindal KK, et al. 2003. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int, 64:295-304.
30. Tsirpanlis G., Bagos P, Ioannou D, et al. 2004. Exploring inflammation in hemodialysis patients: persistent and superimposed inflammation. A longitudinal study. Kidney Blood Press Res, 27:63-70.
31. US Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
32. Wanner C., Richardson D, Fouque D, et al. 2007. OPTA-Influence of inflammation/infection on anaemia therapy in haemodialysis patients. Nephrol Dial Transplant, 22(Suppl 3):iii7-iii12; doi:10.1093/ ndt/gfm015.
33. Wish J.B. 2006. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol, 1: S4-S8.
34. World Health Organization. Nutritional Anaemias. 1968. Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization.